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A Diagnostic Approach to Bone Tumours 
Abstract  
In this review we discuss an approach to diagnosing primary bone tumours namely the cartilaginous, 
bone-forming, giant cell-rich, fibro-osseous and round cell neoplasms. Less common lesions 
including chordoma are also discussed. The value of integrating clinical, histopathological and 
relevant radiological features is emphasised with a view to providing the general Histopathologist 
with a methodical approach to reaching an accurate diagnosis. For more detailed information we 
recommend referring to comprehensive text book on bone tumours recently published (Czerniak, 
2016)1. Key Words: Bone tumours; diagnostic approach; cartilaginous tumours; bone-forming 
tumours; giant cell-rich tumours; fibro-osseous tumours, round-cell tumours, notochord.  
1.1 Introduction 
Primary bone tumours are a heterogeneous group of benign and malignant neoplasms with wide-
ranging histological appearances and genetic alterations. The clinical presentation depends on the 
tumour site but most are associated with pain, particularly at night. Specialist centres for rare 
diseases are good for patients as they benefit from a wealth of experience of a multidisciplinary 
team. 
1.2 Guidelines for how to approach primary bone tumours are described below 
1.2.1 Simple histological classification 
As primary malignant bone tumours represent less than 1% of all cancers, it is best to consider in the 
first instance whether a tumour in bone represents either metastatic carcinoma, a germ cell tumour, 
a primary haematological malignancy, or the consequence of a degenerative or metabolic disorder.  
Once discounted, consider the morphological features and how best to classify the tumour in broad 
terms. 
Primary bone tumour classification: Cartilage-forming, bone-forming, giant cell (osteoclast-rich), 
fibro-osseous, round cell and notochordal.  
Many primary bone tumours comprise of a spectrum of histological phenotypes, for example, an 
osteosarcoma may be chondroblastic; mesenchymal chondrosarcoma exhibits a round cell ‘Ewing-
type’ appearance with islands of chondro-osseous extracellular matrix; chondroblastoma is 
immature cartilage-forming with an osteoclast-rich component; and phosphaturic mesenchymal 
tumour exhibits a range of features and is associated with hypophosphataemia and vitamin D 
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resistant rickets. Once grouped broadly on histological grounds, correlation with the clinical 
information and the imaging should narrow the diagnosis.  
Correlation of the histological findings on a biopsy with imaging is essential: modern imaging 
techniques allow the histological and gross features of a tumour to be appreciated. In most 
circumstances the most ‘worrying’ areas are biopsied.  
 
1.2.2 Location, location, location: access to imaging is essential for musculoskeletal pathologists 
Is the tumour sited ‘in the bone’ (central), ‘on the bone’ (surface) or in the cortex? 
Surface lesions: the differential diagnosis includes the various types of bone tumours described 
below:  
Cartilage-forming: osteochondroma (connected with the underlying bone marrow), periosteal 
chondroma  
Bone and cartilage-forming: bizarre paraosteal osteochondromatous proliferation (BPOP) (generally 
on the hand)  
Bone-forming: a surface osteosarcoma (generally involving the tubular long bones), parosteal 
osteosarcoma  
Fibro-osseous: fibrous dysplasia protuberans, parosteal osteosarcoma   
Osteoclast-rich: aneurysmal bone cyst expanding onto the bone surface 
 
Central bone tumours: where is the lesion sited? 
Epiphyseal: giant cell tumour of bone, chondroblastoma, clear cell chondrosarcoma 
Metaphyseal: osteosarcoma, conventional cartilage-forming tumours, chondromyxoid fibroma, 
aneurysmal bone cyst 
Diaphyseal: osteoblastoma, osteofibrous dysplasia (intra-cortical), adamantinoma (intra-cortical) 





1.3 HISTOLOGICAL FEATURES AND TERMINOLOGY SPECIFIC TO BONE PATHOLOGY  
Entrapment of host lamellar bone – a histological hallmark of malignancy 
1.3.1 Entrapment of host lamellar bone by the tumour, otherwise referred to as ‘a permeative 
growth pattern’ is a diagnostic hallmark of malignancy. This was first described by Mirra2 and reflects 
the speed at which a tumour is growing. The definition of ‘entrapment of host lamellar bone’ is that 
the bone exhibits Howslip’s lacunae on at least three sides (Figure 1D). The absence of this finding 
does not exclude a malignant process and could be explained on the basis of sampling and that the 
tumour is growing so rapidly that the adjacent host bone is completely destroyed.  
1.3.2 Pitfall: if a patient has sustained a fracture or has had previous surgery, host bone can be 
displaced and appear to be ‘entrapped’. 
1.3.3 Encasement of tumour by bone describes a benign process and is generally seen in well 
differentiated cartilaginous tumours. The tumour is surrounded or partly surrounded by bone and 
this reflects that the tumour is growing sufficiently slowly to induce bone formation from cells in the 
bone marrow (Figure 1C). 
 
1.4 CARTILAGE-FORMING TUMOURS 
1.4.1 Cartilaginous tumours (including benign and malignant types) represent the most common 
primary neoplasms of bone, and the most common malignant bone tumours in adults. They are 
classified as conventional and non-conventional. The histology of the former bares a close 
resemblance to non-neoplastic hyaline articular cartilage and includes enchondroma and its 
malignant counterpart conventional central chondrosarcoma, and osteochondroma and its 
malignant counterpart conventional peripheral chondrosarcoma. The non-conventional group 
includes chondroblastoma, chondromyxoid fibroma, dedifferentiated chondrosarcoma, 
mesenchymal chondrosarcoma, and clear cell chondrosarcoma.  
Conventional cartilaginous tumours 
1.4.2 Enchondroma and central chondrosarcoma 
Enchondroma is the most common of all cartilaginous tumours, occurring over a wide age 
distribution (2nd – 7th decades). The true incidence is not known and they are often detected 
incidentally. They may occur in any bone but show a predilection for the small bones of the hands 
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and feet: they are extremely rare at axial sites. They have a characteristic radiological appearance 
(Figure 1A) and correlation with these finding is often essential in reaching a definitive diagnosis.  A 
small proportion progress and transform into central conventional chondrosarcoma (Figure 1B).  
1.4.3 Histologically, enchondromas demonstrate abundant hyaline matrix often encased by a rim of 
mature lamellar bone (Figure 1C). The chondrocytes are present in small numbers, the nuclei of 
which reveal a closed dense chromatin pattern and inconspicuous nucleoli. Histological and 
radiological features of enchondroma and chondrosarcoma grade (G) I are subtle making distinction 
between them nigh impossible: this is confirmed by evidence that there is considerable inter- and 
intra-observer variability between histopathologists making these diagnoses3. Hence we often report 
such tumours as ‘well differentiated cartilaginous’: we prefer not to use the term ‘low grade 
chondral tumours’ as grading a tumour should be restricted to malignant disease. There is good 
correlation between grading on needle biopsy and subsequent resection if the radiology and 
histology are reported by specialists4. Transition from benign (enchondroma) to malignant disease 
GI, GII, GIII is reflected by increasing cellularity, chondrocyte binucleation and a reduction in the 
hyaline matrix with accompanying myxoid change. Grade I tumours have a hyaline matrix and 
chondrocytes with closed pyknotic nuclei and inconspicuous nucleoli. Host bone permeation may be 
identified in which the residual bone trabeculae may be necrotic. Grade II tumours have a myxoid 
and hyaline stroma with chondrocytes showing an open chromatin pattern and conspicuous 
nucleoli. Grade III tumours are highly cellular with nuclear pleomorphism and a mitotic count of two 
or more per 10 high power fields (Figures 1D-F).  
1.4.5 Chondrosarcoma of the small bones of the hands and feet is exceptionally rare5 and a definitive 
diagnosis in this location requires unequivocal host bone permeation with sound radiological 
correlation. The metastatic potential of chondrosarcoma of the small bones of the hands and feet is 
negligible. To reflect this, we conclude our reports with ‘chondrosarcoma of the phalanges has a 
negligible risk of metastasis’.   
1.4.6 Clinical outcome and management 
The management of enchondromas and conventional central chondrosarcoma GI in the long bones 
is generally curettage and the clinical outcome is excellent. Hence, for treatment purposes they can 
be grouped as ‘well-differentiated central cartilaginous tumours’. In contrast, conventional central 
chondrosarcoma GII and III represent high grade disease requiring wide local excision as they have a 
significant risk of local recurrence if curetted, and may metastasise. Patients with chondrosarcoma 
GII have a 50% 5-year survival, with a metastatic potential of 10-15%. Grade III chondrosarcoma 
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represents only 10-15% of all central chondrosarcomas and has an extremely poor prognosis with 5-
year survival rates of approximately 5%, and metastatic potential of 50% 6.  
1.4.7 Isocitrate dehydrogenase type 1 (IDH1) and Isocitrate dehydrogenase type 2 (IDH2) 
mutations  
Mutations in Isocitrate dehydrogenase type 1 and 2 (IDH1/2) in cartilaginous tumours are highly 
specific for enchondromas, central conventional chondrosarcomas, periosteal 
chondroma/chondrosarcoma and dedifferentiated chondrosarcoma but are only seen in 
approximately 60% of such tumours 7. These mutations are not seen in diagnostic mimics including 
osteochondromas, synovial chondromatosis, clear cell, peripheral and mesenchymal variants of 
chondrosarcoma, or osteosarcoma 8.   
 
1.5 Osteochondroma and Conventional Peripheral Chondrosarcoma 
1.5.1 Osteochondroma (exostosis) is a benign conventional cartilaginous tumour. It is a common 
lesion, representing approximately 30% of all bone tumours and presents in two main forms, most 
commonly as a solitary lesion, but also as multiple lesions in the multiple osteochondroma (MO) 
syndrome 9, 10. Most commonly they are seen in long bones particularly at the proximal and distal 
ends of the femur but they can occur in almost any location. Transformation to a high-grade 
(peripheral) chondrosarcoma is uncommon, with high grade peripheral chondrosarcoma accounting 
for no more than 10-15% of all conventional chondrosarcomas 11.  
1.5.2 Radiologically, osteochondroma can be either a broad-based or pedunculated tumour but in all 
cases the stalk is in continuity with the underlying the medullary cavity hence these tumours are 
rarely biopsied prior to resection. X-ray only reveals the calcified and ossified component of a 
cartilaginous tumour and a MRI is required to reveal the uncalcified mass. 
1.5.3 Osteochondroma is characterised by a mature hyaline cartilaginous cap which continues to 
grow until puberty, at which time the growth plate fuses, and the cap, which may reach up to 50mm, 
undergoes calcification and ossification. A narrow cartilaginous cap of a few mm remains and in 
some areas may no longer be visible (Figure 2A). Consequently, any “osteochondroma” with a 
cartilage cap of greater than 20mm in thickness occurring in a mature skeleton is arbitrarily 
considered to represent a conventional peripheral chondrosarcoma (Figure 2B). However, as 
calcification of the cartilage cap occurs over a number of years (after puberty), such measurements 
must be interpreted in the context of the radiological features. 
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1.5.4 The pathologist should slice the tumour to determine the thickness of the cartilage cap, and 
also note if the cartilage extends to the gross excision margins. Osteochondromas resected shortly 
after reaching skeletal maturity at puberty (up to their early 20s) may continue to reveal a hyaline 
cartilage cap measuring focally up to 10-15mm but the presence of calcified areas is indicative of 
involution. Even if quite large (50mm), these tumours rarely invade underlying bone. However, the 
presence of a myxoid and or fleshy matrix is worrying and would suggest transformation to a 
chondrosarcoma.  
1.5.5 Histologically, osteochondromas are characterised by a mature hyaline cartilaginous cap with 
an underlying zone of endochondral ossification, recapitulating the organised appearance of the 
epiphyseal growth plate (Figure 2C).  Peripheral chondrosarcoma GI can grow to a considerable size 
(50-100mm) while retaining a largely hyaline matrix without invading the underlying bone.  Hence, 
the size of the cartilage cap is important. However, the organised cellular arrangement of an 
osteochondroma will be lost in a peripheral chondrosarcoma and replaced by an organoid or clonal 
arrangement of neoplastic chondrocytes, particularly evident on the cap surface. The chondrocytes 
will exhibit an open chromatin pattern although this can be subtle. Management of these lesions is 
made at a bone tumour multidisciplinary meeting. If fully excised peripheral chondrosarcoma GI is 
curable but if centrally placed (in the pelvis) they may be difficult to excise without morbid surgery. 
Incompletely excised tumours may recur and transform into high grade chondrosarcoma or a 
dedifferentiated chondrosarcoma (vide infra), although this is uncommon.  
1.5.6 The histology of GII and GIII disease is like that of central chondrosarcoma (Figure 2D). 
1.5.7 Hereditary multiple osteochondromas is an autosomal dominant disorder characterised by 
mutations in EXT-1 and EXT-2. Sporadic solitary osteochondromas may also harbour these 
mutations. 12, 13.  
1.6 Dedifferentiated Chondrosarcoma  
1.6.1 Dedifferentiation in a chondrosarcoma represents an aggressive complication occurring in 
approximately 10% of central chondrosarcomas but is extremely rare in the peripheral counterpart. 
The presence of a dimorphic tumour on MRI in which one component shows the features of a low 
grade chondral tumour (i.e. a lobular morphology with a high T2 signal) combined with features of a 
spindle cell sarcoma on biopsy suggests this diagnosis. Histologically, it is characterised by a 
conventional chondrosarcomatous component, usually GI or GII, abutting a high-grade sarcoma with 
an undifferentiated appearance 14, 15. Heterologous elements, most commonly osteosarcomatous 
can be seen but rhabdomyosarcomatous and osteoclast-rich elements also occur potentially leading 
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to a misdiagnosis of osteosarcoma, rhabdomyosarcoma/Triton tumour, and a giant cell tumour of 
bone respectively. Distinguishing between a primary osteosarcoma and a dedifferentiated 
chondrosarcoma usually has management implications: osteosarcoma is generally treated with 
neoadjuvant chemotherapy whereas this is not the case for chondrosarcoma. Radiological and 
demographic data can be very helpful in making the distinction however in difficult cases the 
identification of an IDH1 or an IDH2 mutation establishes of the diagnosis of dedifferentiated 
chondrosarcoma. However, these substitutions only occur in approximately 60% of such tumours 7. 
There are now targeted therapies available against mutant IDH1 and IDH2 and failure to detect such 
mutations could potentially deny a patient being offered entry into on-going early phase clinical 
trials 16. 
1.7 Ollier disease and Maffucci syndrome (Multiple enchondromas) 
1.7.1 Ollier disease and Maffucci syndrome represent the most common form of multiple 
enchondromas and are genetically related non-familial disorders. Ollier disease is characterised by 
multiple enchondromas, and Maffucci syndrome has the additional features of soft tissue (and more 
rarely visceral) spindle cell haemangiomas. Early post-zygotic somatic mutations in IDH1, and less 
commonly IDH2, account for this mosaic disorder in virtually all cases. Hence, detection of an IDH1/2 
mutation does not help grade a cartilaginous tumour occurring in these syndromic patients as it is 
present ab initio – from enchondroma through to dedifferentiated chondrosarcoma 7, 17. Patients 
with these syndromes are at risk of developing chondrosarcoma in addition to many other 
malignancies including glioma, glioblastoma multiforme and acute myeloid leukaemia. Individuals 
with multiple enchondromas without IDH1/2 mutations are likely to have another form of multiple 
enchondromas syndrome, such as metachondromatosis (PTPN11) 18 and 
spondyloenchondrodysplasia (ACP5) 19, and others as yet without a known genetic alteration. 
1.8 Non-conventional cartilaginous tumours 
1.8.1 Chondroblastoma 
Chondroblastoma occurs at the epiphysis of the long bones and at apophyseal sites most commonly 
presenting in skeletally immature individuals. Histologically, the constituent neoplastic cell is the 
chondroblast (Figure 3A).  Over 95% of chondroblastomas harbour a H3F3 K36M mutation, a highly 
specific marker which can be detected by a highly sensitive antibody 20, 21. Chondroblastomas 
generally contain an osteoclast-rich component, thereby being included in the differential diagnosis 
of osteoclast-rich tumours 22. Secondary aneurysmal bone cyst is not uncommonly associated with 
chondroblastoma but the presence of even a few H3.3 K36M mutant-positive cells on 
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immunohistochemistry provides the diagnosis. In the absence of this characteristic mutation, 
chondromyxoid fibroma and phosphaturic mesenchymal tumour (PMT), the latter showing a 
“grungy” pattern of calcification should be considered. PMT is generally associated with low levels of 
blood phosphate levels and osteomalacia as a consequence of high levels of fibroblastic growth 
factor 23 (FGF23) which can be detected using an in situ hybridisation technology – RNAScope 23. 
1.8.2 Chondromyxoid Fibroma 
Chondromyxoid fibroma is a non-conventional benign bone tumour showing cartilaginous 
differentiation with a predilection for the metaphysis of the tubular long bones and the flat bones of 
the hands and feet. It occasionally occurs within the flat bones of the pelvis where it presents as an 
incidental finding. Histologically, the tumour is well demarcated from the adjacent non-neoplastic 
bone and has a myxoid stroma with lobulation reflecting cellular and less cellular areas and true 
hyaline cartilage with lacuna formation is rare. The tumour cells may show nuclear pleomorphism 
and hyperchromasia potentially leading to an erroneous diagnosis of a conventional 
chondrosarcoma 24. Mitoses and necrosis are exceptionally rare in chondromyxoid fibroma (Figure 
3B).  The differential diagnosis includes phosphaturic mesenchymal tumour: measurement of 
calcium and phosphate in the blood can help resolve this. 
Chondromyxoid fibromas are characterised by chromothripsis on chromosome 6q in more than 90% 
leading to upregulation of glutamate receptor metabotropic-1 (GRM1) 25. As yet the identification of 
this complex rearrangement is not used in clinical practice for diagnostic purposes. 
1.8.3 Bizarre Paraosteal Osteochondromatous Proliferation (BPOP) 
Bizarre parosteal osteochondromatous proliferation (BPOP), also known as Nora’s lesion 26, is a 
benign, locally recurring surface tumour of the small bones of the hands and feet most commonly 
presenting in the 2nd and 3rd decades of life . Rarely it may affect the tubular long bones and less 
commonly the craniofacial skeleton (Figure 3C). Their often-rapid growth can give rise to clinical 
suspicion of malignancy, compounded by histologically complex features of a bone and cartilage-
forming lesion which can lead the unwary to concerns about a chondrosarcoma or an osteosarcoma. 
However, the site and size of a BPOP, together with the absence of atypical mitoses, host bone 
entrapment and a periosteal reaction generally excludes a high-grade bone sarcoma. Re-excision of 
a locally recurrent lesion is recommended. Malignant transformation has not been reported.  
Radiologically the tumour is “stuck on” to the bone surface showing no continuity with the 
medullary cavity, helping to differentiate it from an osteochondroma. However imaging may not be 
available.  
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1.8.4 Mesenchymal chondrosarcoma 
This rare tumour occurs in bone and soft tissue. Favoured sites include the craniofacial skeleton, the 
ribs and vertebrae. It commonly presents in the 2nd and 3rd decades. The histological appearance is 
highly characteristic (Figure 3D). In the absence of sampling the chondro-osseous component, it is 
easy to misdiagnose as Ewing sarcoma. Molecular pathology tests are valuable for reaching a 
diagnosis, as the identification of the characteristic HEY1-NCOA2 fusion gene 27 is mutually exclusive 
with the genetic alteration characteristic of Ewing sarcoma. 
BONE-FORMING TUMOURS 
1.9 Osteoid osteoma and osteoblastoma 
1.9.1 Osteoid osteoma and osteoblastoma are benign bone-forming tumours occurring in the 
cortical and medullary bone respectively. They involve the metaphyseal/diaphyseal region of the 
tubular long bones (most commonly distal femur), the vertebral bodies, and the small bones of the 
hands and feet 28. The pain of osteoid osteoma is characteristically relieved significantly by non-
steroidal anti-inflammatory drugs which is not the case for osteoblastoma. Both osteoid osteoma 
and osteoblastoma have circumscribed margins radiologically and histologically and osteoid 
osteoma usually has prominent associated surrounding sclerosis. Both have a central nidus which 
can be seen histologically and arbitrary measurements are used to distinguish them (less than 20 
mm in the osteoid osteoma and >20 mm in osteoblastoma). In both, the nidus is composed of 
irregular anastomosing bony trabeculae showing very prominent osteoblastic rimming with an 
intervening richly vascularised stroma (Figure 4) 28. Osteoclasts may also be conspicuous. 
Osteoblastomas showing striking cellular atypia are referred to as bizarre and/or aggressive 
osteoblastomas but the clinical outcome does not differ to those without these atypical cells. 
Secondary aneurysmal bone cyst formation may occur.  
2.0 Osteosarcoma 
2.0.1 Osteosarcoma is the most common primary non-haematopoietic tumour of bone, 
characterised by osteoid-producing malignant cells. It rarely occurs before the age of 4, and is most 
commonly seen between the ages of 10 and 14, but 30% occur over the age of 40.  Extraskeletal 
osteosarcomas are classified based on anatomical location (i.e soft tissue with no skeletal 
continuity), and their differential diagnosis includes malignant peripheral nerve sheath tumour, and 
dedifferentiated liposarcoma with heterologous bone forming elements.  
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2.0.2 High grade osteosarcoma of bone is treated with neoadjuvant chemotherapy: the response to 
treatment is one of the most important prognostic indicators of overall and disease-free survival. A 
good response to chemotherapy is defined as >90% tumour necrosis post-treatment (Figure 5A, B).  
2.0.3 There are various osteosarcoma subtypes classified on the basis of grade (low and high), 
morphology and anatomical site (central and surface). Central tumours are most common, and most 
are high grade: these include osteoblastic (70-80%) chondroblastic (10-15%), 
fibroblastic/pleomorphic (10%), telangiectatic (<4%), and rare variants (giant cell-rich, small cell, 
osteoblastoma-like) (Figure 5). High grade surface osteosarcoma is extremely rare and is treated the 
same as high grade centrally-sited tumours. Low grade osteosarcomas are also rare, representing 4% 
of all skeletal osteosarcomas: they arise in the medullary space (low grade central osteosarcoma, 
1%) 29; and on the bone surface (parosteal osteosarcoma, 3%). Parosteal osteosarcoma may 
transform to high grade disease (in 10-15% of cases), referred to as dedifferentiated parosteal 
osteosarcoma. Another exceptionally rare surface variant is known as periosteal osteosarcoma (vide 
infra).  
2.1 Tips when reporting osteosarcoma 
2.1.1 Osteoid deposition associated with highly atypical cells is the characteristic feature of high-
grade osteosarcomas but the amount varies considerably. It is generally abundant in the osteoblastic 
type and can be minimal in the telangiectatic subtype. The morphological variants of high grade 
osteosarcoma do not influence the management of the disease or predict a response to treatment. 
2.1.2 The large cells with low nuclear: cytoplasmic ratio in ‘bizarre’ osteoblastoma can be mistaken 
for osteosarcoma. 
2.1.3 Aneurysmal bone cyst can be mistaken for telangiectatic osteosarcoma and vice versa. 
2.1.4 Primary high grade fibrosarcoma or pleomorphic sarcoma in bone in which no osteoid is 
identified are generally managed with the same chemotherapeutic regime as an osteosarcoma. 
However, before making such a diagnosis it is important to exclude that the lesion does not 
represent a soft tissue tumour extending into bone, a dedifferentiated chondrosarcoma or 
metastatic disease (e.g. sarcomatoid renal cell carcinoma) from elsewhere. Imaging may help 
identify bone formation in cases where matrix is not noted in the biopsy, confirming a diagnosis of 
osteosarcoma and guiding management. 
2.1.5 It can be difficult to distinguish a chondroblastic osteosarcoma from a conventional 
chondrosarcoma. Focussing on the degree of the chondrocyte atypia and the volume of extracellular 
matrix is helpful. In general, the severity of the nuclear atypia in chondroblastic osteosarcoma is 
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discordant with the amount of myxoid matrix, that is there is severe atypia and a significant amount 
of cartilaginous matrix (Figure 5D). Imaging and demographics should be considered.  
2.1.6 Immunohistochemistry is not generally helpful in reaching a diagnosis: cytokeratins, S100 and 
other markers can be expressed in osteosarcoma. SATB2 is not specific for osteosarcoma. 
2.1.7 Small cell osteosarcoma is exceptionally rare: Ewing sarcoma, lymphoma, carcinoma, 
mesenchymal chondrosarcoma, and histiocytic neoplasms should be excluded before proving this 
diagnosis. 
2.1.8 Most osteosarcomas represent primary disease, but a small percentage particularly in those 
presenting >40 years is secondary to irradiation, Pagetic disease, fibrous dysplasia, giant cell tumour 
of bone30, and bone infarction.  
2.1.9 Approximately, 20% of patients with osteosarcoma harbour a germline genetic mutation, most 
commonly involving TP53 causing Li-Fraumeni syndrome, bilateral retinoblastoma syndrome, and 
Rothmund-Thomson syndrome 31. 
The somatic genetic alterations in osteosarcoma reveal that structural variants represent the 
predominant source of mutations and that there is a diverse landscape of driver genes: nearly 30% 
exhibit chromothripsis on one or more chromosomes, and a distinct copy number pattern of 
combined chromothripsis and amplification occurred in approximately 60% of cases32. 
 
2.2 Low Grade Central Osteosarcoma 
2.2.1 Low grade central osteosarcoma most commonly occurs in the third decade of life and favours 
the tubular long bones, in particular the distal femur and proximal tibia. If completely excised and in 
the absence of an associated high grade component, the prognosis is good with only 15% of tumours 
metastasising. Histologically the tumour is composed of fascicles of mildly atypical spindle cells and 
may exhibit a fibrous dysplasia-type phenotype (Figure 5F), however as GNAS mutations are 
detected in >95% of FD cases, the absence of such a mutation largely excludes this diagnosis 33. In 
contrast, the detection of a GNAS mutation does not completely exclude a diagnosis of an 
osteosarcoma as 1% of fibrous dysplasia transforms into osteosarcoma. Entrapment of host lamellar 
bone is helpful in reaching a malignant diagnosis. Imaging is important to assess for lack of a 
homogeneous signal and can direct the site from where a biopsy should be taken. Following 
resection extensive sampling is required to exclude transformation to high grade disease.  
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2.2.2 Approximately 40% of low grade central osteosarcomas harbour amplification of MDM2 and 
this is mutually exclusive with GNAS mutations which occur in fibrous dysplasia. GNAS mutations are 
rarely if ever detected in low grade central osteosarcomas 33. 
SURFACE OSTEOSARCOMA 
2.3 Parosteal Osteosarcoma 
2.3.1 Paraosteal osteosarcoma is the most common of the surface osteosarcoma variants, occurring 
in adults most commonly in the third decade of life. If fully excised survival is good but reports 
indicate that if incompletely excised, there is a high recurrence rate, which may be many years later 
with transformation to high grade disease (sometimes referred to as ‘dedifferentiation’) and risk of 
metastasis. In one series, 40% of recurrences of parosteal osteosarcoma were associated with de-
differentiation 34. The tumour arises directly from the external layer of the periosteum in a highly 
characteristic location with approximately 80% occurring on the posterior aspect of the metaphysis 
of the distal femur. Approximately half of parosteal osteosarcomas show cartilaginous 
differentiation, which can be extensive. It may be distributed throughout the tumour or take the 
form of a cartilaginous cap causing it to be mistaken for an osteochondroma. However, unlike an 
osteochondroma, parosteal osteosarcoma is ‘stuck on’ to the cortical bone and lacks continuity with 
underlying medullary bone. 
2.3.2 Parosteal osteosarcoma histologically is composed of cellular fascicles of mildly to moderately 
atypical spindle cells interspersed with parallel bony trabeculae. The presence of a more densely 
cellular tumour with nuclear pleomorphism and conspicuous mitotic activity is characteristic of 
transformation to high grade disease. However, distinguishing low from high grade disease is 
subjective and not always easy. High grade disease is associated with a more aggressive course and a 
poorer prognosis. Genetically parosteal osteosarcoma, irrespective of grade, shows amplification of 
MDM2 and CDK4 in approximately 85% of cases 35; to date there is no objective biomarker defining 
transformation to high grade disease. 
2.4 Periosteal Osteosarcoma 
2.4.1 Periosteal osteosarcoma is an exceptionally rare variant of osteosarcoma: it is an intermediate 
grade surface tumour most commonly occurring in the second and third decades of life. It shows a 
predominant chondroblastic morphology, and osteoid is usually focal. There is no characteristic 
genetic alteration reported. Periosteal osteosarcoma has a better prognosis as compared to 
conventional osteosarcoma with approximately 80% of patients surviving long term 36 and has 
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therefore come to be classified as an intermediate grade tumour. This rare tumour is managed with 
neo-adjuvant chemotherapy followed by surgical resection.  
 
2.5 OSTEOCLAST CELL-RICH TUMOURS 
Assessment of serum calcium and phosphate levels should be undertaken in all osteoclast-rich 
lesions to exclude hyperparathyroidism and other metabolic diseases where a definitive diagnosis 
based on molecular findings has not been proven. 
The differential diagnosis of giant cell tumours includes aneurysmal bone cyst, chondroblastoma, 
giant cell granuloma of the jaw and small bones of the hand and feet, brown tumour of 
hyperparathytroidism, fibrous dysplasia, Pagetic bone disease and osteoclast-rich lesions of the jaw 
seen in germline disorders including Cherubism, Noonan syndrome, and Neurofibromatosis 37, 38. 
Multiple osteoclast-rich tumours require further investigation to exclude hyperparathyroidism and 
germline conditions. Multiple giant cell tumours with H3F3A G34W mutations has been recently 
reported to occur as part of a mosaic disorder in conjunction with paragangliomas and other 
tumours. Multiple giant cell tumour-type/non-ossifying fibroma-type lesions can also occur in the 
presence of the linear naevus sebaceous syndrome, associated with HRAS/KRAS mutations. 
 
2.6 Giant cell tumour of bone 
2.6.1 Giant cell tumour of bone is a locally aggressive and rarely metastasising tumour, occurring in 
the epiphysis of the long bones. It is exceptional to see this tumour in the immature skeleton. Most 
present in the second to fourth decades.  Favoured sites are the distal femur and proximal tibia 
followed by the distal radius and the sacrum. 
2.6.2 The most common treatment is curettage and cementation however if tumour recurs or 
involves the joint, a wide resection with a prosthetic implant may be required. Denosumab, a RANKL 
inhibitor, is now employed for the treatment of giant cell tumours in surgically inaccessible sites 
such as the pelvis and sacrum, and base of skull. This inhibitor blocks recruitment of osteoclasts 
resulting in maturation of the neoplastic cells and bone formation. The histological changes 
associated with Denosumab many lead to the erroneous diagnosis of osteosarcoma 39. 
 
2.6.3 Histologically, giant cell tumours of bone are composed of large osteoclasts containing up to 
100 nuclei with interspersed mononuclear cells, representing the neoplastic component (Figure 6A). 
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These cells express high levels of receptor activator nuclear factor κ-B (RANKL), which accounts for 
the recruitment of the osteoclast-like giant cells as a non-neoplastic reactive population. Mitotic 
figures may be seen in large numbers although the presence of atypical forms raises concerns of a 
sarcoma. More than 95% of giant cell tumours of bone harbour a p.G34 point mutation in the H3F3A 
gene. This mutation is only detected in the mononuclear cell component, confirming these as the 
neoplastic element of giant cell tumour of bone (Figure 6B). The vast majority of mutations are 
represented by p.G34W but p.G34L occurs in small numbers. The former can be detected by 
immunohistochemistry, simplifying the diagnosis of these tumours 40. The antibody is highly 
sensitive and specific for this diagnosis41.  However as approximately 2% of osteosarcomas also 
harbour a H3.3 G34 mutation it is not possible to rely purely on the presence of this alteration for 
making a diagnosis of giant cell tumour of bone: morphological, radiological and clinical correlation 
remain essential41.   
 
2.6.4 The main challenge to making a diagnosis of giant cell tumour of bone is to distinguish it from 
an osteoclast-rich osteosarcoma. For this, histological assessment remains the gold standard: 
osteoclast-rich osteosarcoma and malignant giant cell tumour of bone show significant atypia in the 
mononuclear cell component, often with atypical mitoses, not seen in giant cell tumours of bone. 
Rarely, a dedifferentiated chondrosarcoma exhibits an osteoclast-rich component: detection of an 
IDH1/2 mutation allows the diagnosis to be made but the absence of such a mutation is not helpful. 
2.7 Primary aneurysmal bone cyst (ABC) 
2.7.1 ABC is an intramedullary osteolytic tumour presenting in any bone over a wide age range but 
usually in patients under 30. Genetically it is characterised by a USP6 fusion gene in 70% of cases. As 
there are a wide range of fusion partners, FISH is the best clinical test available at present for 
detection of the USP6 rearrangement. An identical molecular signature also occurs in nodular 
fasciitis 42. 
2.7.2 Histologically, the tumour is composed of solid and cystic areas in varying proportions: there 
are blood-filled spaces surrounded by with fibrous septae often containing osteoid seams, 
sometimes exhibiting a blue hue, referred to as ‘blue bone’ (Figure 6C). Secondary aneurysmal bone 
cyst is a frequent reactive morphological appearance associated with any primary bone tumour, 
although most commonly seen with benign lesions. This component does not harbour the USP6 
alteration seen in the primary ABC. The presence of secondary bone cyst change can account for 
rapid and worrying expansion of a benign tumour. 
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2.8 Non-ossifying fibroma 
2.8.1 Non-ossifying fibroma (metaphyseal fibrous defect) is a fibrohistiocytic lesion occurring in the 
metaphyseal region of tubular long bones, typically in skeletally immature individuals with a 
characteristic imaging appearance Image. Favoured sites include the distal femur and the proximal 
and distal ends of the tibia. Histologically, non-ossifying fibroma is composed of bland spindle-
shaped cells and macrophages with a storiform architecture (Figure 6D). They often undergo 
spontaneous involution, raising the possibility that they represent a reactive rather than neoplastic 
process. See section on multifocal osteoclast-rich lesions 37, 38.  
 
2.9 Giant cell-rich lesions of the craniofacial skeleton 
2.9.1 A wide range of giant cell rich lesions occur in the craniofacial skeleton, some of which are 
associated with specific diseases with germline alterations, namely neurofibromatosis/Jaffe 
Campannacci syndrome (NF1), Cherubism (SH3BP2), and Noonan/Leopard syndrome (most 
commonly PTPN11, but also KRAS, BRAF, HRAS, and others) 43. Central and peripheral reparative 
giant cell granulomas are distinguished radiologically by continuity with the bone, and pure soft 
tissue involvement, respectively. If a central giant cell granuloma recurs or behaves aggressively, 
consideration should be given to whether the patient may harbour one of the aforementioned 
germline disorders. The lesions occurring on the background of one of these germline disorders 
exhibit similar morphologies to a non-ossifying fibroma. However, the histological spectrum extends 
to those found in giant cell tumour of bone. Giant cell tumour of bone (defined as harbouring a H3.3 
G34W mutation) has not been reported in the jaw 44. 
FIBRO-OSSEOUS TUMOURS 
3.0 Fibrous Dysplasia 
3.0.1 Fibrous dysplasia is a central benign neoplastic fibro-osseous tumour presenting in monostotic 
(75%) or polyostotic (25%) forms. Any bone can be affected and the imaging is characterised by a 
‘ground glass’ appearance on x-ray. The lesion should not ‘break through’ the cortical bone although 
this can occur in ‘thin’ bones such as the skull, ribs and small bones of the hand. Presenting 
symptoms include pain, deformity, fracture and cranial nerve defects, depending on the bone 
involved.  
3.0.2 Fibrous dysplasia is associated with hypophosphatemia in 10% of cases hence calcium and 
phosphate should be measured in all affected patients 45. We like to include this recommendation in 
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our pathology report. The hypophosphatemia is caused by fibroblastic growth factor 23 being 
secreted by tumour cells and exerting a systemic effect on the kidneys.  This can result in bowing of 
the legs and skeletal deformities in the immature/growing skeleton and requires treatment. Referral 
to a metabolic bone specialist is recommended.   
3.0.3 Histologically, fibrous dysplasia is characterised by bland monotonous spindle cells in which 
variable amounts of immature woven bone (appreciable on polarisation) is seen, arranged in 
irregular angulated and curvilinear trabeculae – so-called “Chinese characters.” The bony trabeculae 
lack osteoblastic rimming (in contrast to osteofibrous dysplasia – vide infra)46. Mitotic figures are not 
common, although more so in children, and should consequently arouse suspicion of malignancy.  
3.0.4 The main differential diagnosis of fibrous dysplasia is a low grade central osteosarcoma, and if 
protruding out of the medullary cavity, a parosteal osteosarcoma. GNAS mutations and MDM2 
amplification are mutually exclusive, helping to distinguish these lesions 33. Osteofibrous dysplasia 
should always be considered in the differential diagnosis in the tibia and fibula, and 
immunohistochemistry for broad-spectrum cytokeratins always performed. The presence of 
cytokeratin expression and GNAS mutations are mutually exclusive.  Fibrous dysplasia may also be 
associated with intra-muscular myxoma, Mazabraud syndrome, which also harbours the GNAS 
mutation as part of the mosaic disorder.  
3.1 Osteofibrous dysplasia is a benign cortical-based tumour occurring essentially only in the tibia 
and fibula. It may be associated with a cMET germline mutation, when it presents bilaterally in 
young patients 47. These mutations have not been detected in the sporadic variant of the disease. 
Histologically, it is very similar to fibrous dysplasia but is distinguished by osteoblastic rimming of the 
bony trabeculae and the presence of cytokeratin-positive cells, a feature which is mutually exclusive 
with the presence of GNAS mutations. Osteofibrous dysplasia is considered to be the precursor of 
adamantinoma, although this transition is a rare event. 
NOTOCHORDAL TUMOURS 
3.2 Chordoma 
3.2.1Chordoma is a malignant tumour showing notochordal differentiation and is considered to 
originate from persistent midline embryonic notochord elements. Chordoma is a sporadic disease in 
the vast majority of cases and may exceptionally be inherited as an autosomal dominant trait, 
brought about by tandem duplication of the brachyury gene, otherwise known as T. Chordoma 
occurs in the axial skeleton from the spheno-occipital region/base of skull to the sacro-coccygeum: it 
occurs very occasionally in extra-axial bone, and soft tissue sites 48. Chordoma presents at all ages 
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from birth but most commonly in the 5th and 6th decades. In the paediatric age group, they occur 
most commonly in the spheno-occital region and the cervical spinal column. The median survival is 7 
years. Metastases present late, usually several years after initial presentation, with spread to other 
bones and unusual sites such as the subcutaneous tissue. The mainstay of management is surgery in 
association with particles or photons, allowing higher doses of radiation 49. EGFR inhibitors have 
been identified as a potential new therapeutic option 50.  
3.2.2 Most chordomas exhibit a typical histology (Figure 7A), and given their clear cell morphology, 
the differential diagnosis includes metastatic carcinoma and chondrosarcoma. The diagnostic 
challenge is compounded by the fact that chordoma expresses cytokeratin51. However, brachyury 
expression, the diagnostic hallmark of chordoma except in the dedifferentiated variant, is rarely 
seen in carcinoma (Figures 7B and7C) 49. Chondroid differentiation may be noted but these cells also 
express brachyury and this morphology does not appear to influence the clinical outcome or 
treatment. 
3.2.3 Benign notochordal cell tumour (BNCT) arises in the same anatomical regions as chordoma 52. 
Radiologists can generally make the diagnosis on imaging and therefore they are rarely biopsied. 
There is no consensus on how to monitor patients in whom these lesions are identified. 
Histologically they can be mistaken for adipose tissue but express brachyury and cytokeratins (Figure 
7D). Occasionally these are found adjacent to chordoma providing supportive evidence that they 
represent a precursor tumour. BNCT has a notochordal phenotype but does not show permeation 
into the host bone or soft tissue involvement. Ecchordosis physaliphoroa is a benign notochordal cell 
tumour occurring in the spheno-occipitalial region. 
ROUND CELL TUMOURS 
3.3 EWING SARCOMA AND EWING SARCOMA FAMILY OF TUMOURS (ESFT) 
 
A diagnosis of a ‘round cell tumour’ should rarely be given today as most tumours with this 
morphology can be classified on the basis of a genetic event and or immunohistochemistry.  
Most ESFT harbour an EWSR1 rearrangement, however EWSR1 alterations are found in many other 
tumour types including clear cell sarcoma, angiomatoid fibrous histiocytoma, myoepithelioma, 
extraskeletal myxoid chondrosarcoma and desmoplastic small round cell tumour. As such, 
morphological evaluation is paramount. 
3.3.1 Ewing sarcoma is a malignant “small round cell” tumour showing neuroectodermal 
differentiation. Previously sub-classified as peripheral neuroectodermal tumours (PNET), Askin 
tumours and others these are now collectively referred to as the Ewing sarcoma family of tumours 
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(ESFT). They occur at all sites, both in bone and soft tissue, although 80% of those in bone present in 
children whereas the soft tissue tumours mainly occur in adults. They are typically sited in the 
metaphyseal/diaphyseal region of the tubular long bones of the extremities. Clinically the tumour 
may mimic osteomyelitis presenting with pain, fever, weight loss and leucocytosis. The prognosis of 
Ewing sarcoma has dramatically improved since the advent of modern chemo-therapeutic regimes in 
the 1980s but little thereafter. The 5-year survival rates for localised tumours is approximately 70-
80% but only 15-30% for tumours which are metastatic at presentation 53. 
3.3.2 Histologically, Ewing sarcomas exhibit a monotonous “small round cell” appearance with 
membranous immunoreactivity for CD99 but they occasionally show a more pleomorphic 
morphology (atypical Ewing sarcoma), with less prominent CD99 expression (Figure 8A, B). CD99 has 
poor specificity and positivity should be combined with identification of a recurrent genetic 
alteration for diagnostic confirmation of Ewing sarcoma. 90% harbour an EWS-FLI1 fusion gene 
(Figure 8C). Other fusion partners have been described, including ERG and ETV1. In addition, there 
are tumours referred to as Ewing-like sarcomas representing part of the ESFT lacking the 
characteristic molecular signature. These tumours show a predominantly round cell appearance 
although with a more varied morphology: they are characterised by translocations in CIC-DUX4, and 
BCOR-CCNB3 (Figure 8D). The latter occurs in bone. Although it is a contentious issue as to whether 
these tumours belong to the Ewing family of sarcomas, they are currently treated with the same 
neoadjuvant chemotherapy regimens54. There are new potential emerging diagnostic markers 
detectible by immunohistochemistry such as NKX2-2, a downstream target of EWSR1-FLI1. This 
marker is sensitive but not specific for the diagnosis of Ewing sarcoma, being expressed in other 
tumours including mesenchymal chondrosarcoma, CIC-DUX4 and BCOR-CCNB3 rearranged round cell 
sarcomas, meaning it may have limited diagnostic utility55.   
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Figure 1: Enchondromas and conventional central chondrosarcoma. 
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A. Enchondroma (MRI): a well-defined expansile lobular chondral tumour within the proximal 
aspect of the proximal phalanx of the left fifth toe showing a characteristic punctate pattern 
of calcification without exciting a periosteal reaction, or extending into soft tissues. 
B. Chondrosarcoma GII (MRI): a patient with Ollier’s disease showing multiple chondral 
tumours. The largest tumour is present at the superior aspect of the left iliac crest and left 
supra-acetabular region. The tumour has a heterogeneous appearance with osseous 
destruction and an accompanying periosteal reaction.  
C. Enchondroma (H&E x40): a cartilaginous tumour with a hyaline matrix containing evenly 
distributed chondrocytes with closed pyknotic nuclei (closed chromatin pattern) that may be 
mistaken for mitotic figures. The mature cartilaginous tumour is encased by a rim of lamellar 
bone: no host bone permeation is noted (*). 
D. Conventional central chondrosarcoma, GI (H&E x40): a cartilaginous tumour with a hyaline 
matrix showing slight disorganisation of the chondrocytes, but the nuclei exhibit a closed 
chromatin pattern. Extensive host bone permeation is noted with formation of Howslip’s 
lacunae appreciated, confirming malignancy (*).  
E. Conventional central chondrosarcoma, GII (H&E x100): a hypercellular cartilaginous tumour 
with myxoid stromal change and spindled tumour cells with an open chromatin pattern and 
prominent nucleoli.  
F. Conventional central chondrosarcoma, GIII (H&E x200): highly atypical cells with an open 
chromatin pattern and hyperchromasia. Mitotic activity is easily appreciated. Two or more 
figures/10 high power fields classifies the tumour as grade III 56. 
Figure 2: Osteochondroma and conventional peripheral chondrosarcoma. 
A. Osteochondroma: an outer fibrous peri-chondrial layer with an underlying hyaline 
cartilaginous cap, showing variable calcification. The uncalcified portion of the cartilaginous 
cap measures <20mm, a reassuring feature supporting a benign lesion.  
B. Conventional peripheral chondrosarcoma: the uncalcified portion of the cartilaginous cap is 
>20mm with an irregular nodular configuration: this is indicative of malignant 
transformation in skeletally mature individuals.  
C. Osteochondroma, (H&E x20): a mature hyaline cartilaginous cap featuring organised 
chondrocytes with a closed chromatin pattern and underlying endochondral ossification. No 
permeation into the underlying medullary bone is seen. The uncalcified portion of the 
cartilaginous cap is marked with a double-headed arrow. Only this portion of the 
cartilaginous cap is considered when assessing for malignant transformation. 
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D. Conventional peripheral chondrosarcoma, GII (H&E x40): note the hyaline stroma and 
disorganised chondrocytes. The uncalcified portion of the cartilaginous cap in this case 
measures 35mm. 
 
Figure 3: Non-conventional cartilaginous tumours. 
A. Chondroblastoma (H&E x100). Oval neoplastic chondroblasts with eosinophilic cytoplasm 
are distributed throughout. Note the focal calcification, which if extensive, imparts a so-
called characteristic “chicken wire” appearance. Inset: Immunohistochemistry for H3F3 
K36M showing nuclear positivity, confirming the diagnosis.  
B. Chondromyxoid fibroma (H&E x100). The tumour cells have a spindled to stellate 
morphology with amphopihilic cytoplasm and a closed chromatin pattern set in a myxoid 
cartilaginous matrix. Peripheral cellularity imparts a pseudo-lobular appearance. No mitotic 
figures or necrosis is appreciable, helping to differentiate this tumour from a 
chondrosarcoma, GII. This can be confirmed by radiological correlation.  
C. BPOP (H&E x20). A surface-based cellular fibro-osseous cartilaginous tumour showing the 
osseous component here with a strong haemotoxyphilic ‘blue’ staining pattern. Note there is 
no cytological atypia. The lesions are small and often scraped off thus the histology is 
disrupted and imaging may not be available. 
D. Mesenchymal chondrosarcoma (H&E x40). A bi-phasic tumour represented by well-
differentiated cartilage and primitive monotonous malignant “small round blue cells”. A 
prominent haemangiopericytomatous vascular pattern is also noted. 
 
Figure 4: Osteoid osteoma 
Microscopy (H&E x40). The figure demonstrates a central nidus of an osteoid osteoma. Plump 
osteoblasts and conspicuous osteoclasts line the bone trabeculae. Between the trabeculae there is 
conspicuous vascularity.  The nidus is surrounded but more mature bone (arrow) present at the 
periphery. These features are also seen in osteoblastoma. When interpreted in the context of the 
radiological features, this tumour should not be misdiagnosed as osteosarcoma. 
 
Figure 5: Conventional Osteosarcoma. 
 21 
A. A high grade osteoblastic osteosarcoma post-chemotherapy-treated distal femoral 
resection. A metaphyseal-diaphyseal-sited tumour with extension to the epiphysis. Cortical 
breach with periosteal elevation (Codman’s triangle) and soft tissue extension are 
appreciated. 
B. The percentage of response to pre-operative chemotherapy requires histological assessment 
of a complete cross section of the specimen (bone slab). 
C. High grade osteoblastic osteosarcoma (H&E x100). Tumour cells with a high-grade 
morphology with marked nuclear pleomorphism and atypical mitoses. Osteoid deposition is 
extensive.  
D. High grade chondroblastic osteosarcoma (H&E x100). Malignant tumour with chondroblastic 
features showing a myxo-hyaline cartilaginous matrix with pleomorphic tumour cells. The 
degree of nuclear atypia combined with the hyaline quality of the matrix favours a diagnosis 
of chondroblastic osteosarcoma. Osteoid deposition varies but is sparse in this case. 
E. High grade fibroblastic osteosarcoma (H&E x40). Osteoid production with pleomorphic 
tumour cells set in a densely collagenised stroma. Host bone entrapment is noted with 
formation of Howslip’s lacunae (**). 
F. Low grade central osteosarcoma (H&E x40). Mildly atypical spindle cells arranged in a 
fascicular architecture and irregular bony trabeculae showing entrapment of adjacent host 
bone. 
 
Figure 6 Osteoclast Cell Rich Tumours. 
A. Giant cell tumour of bone (H&E x100):  The neoplastic mononuclear cells are oval with 
moderate amounts of eosinophilic cytoplasm and occasionally prominent nucleoli. 
Osteoclast-like giant cells are evenly distributed throughout. There is no cytological atypia 
within the mononuclear cells or atypical mitoses, helping to exclude an osteoclast-rich 
osteosarcoma. Scattered typical mitoses may be seen. 
B. G34W Immunohistochemistry (H&E x100): Nuclear immunoreactivity within the 
mononuclear cells confirming the presence of a H3.3 G34W mutation. Note the lack of 
reactivity in the osteoclast-like giant cells serve as an internal negative control.  
C. Aneurysmal bone cyst (H&E x40): Cystic tumour in which the neoplastic component is 
represented by inconspicuous monotonous spindle cells. Not the osseous metasplasia with a 
characteristic blue hue so-called “blue bone” (*). Inset: FISH for USP6 using a break apart 
probe showing a split signal, confirming the presence of a rearrangement.  
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D. Non-ossifying fibroma (H&E x100): Metaphyseal lesion composed of monomorphic spindle 
cells with a fibro-histiocytic morphology with a storiform architecture associated with 
numerous foamy histiocytes and scattered osteoclast-like giant cells: the inset shows 
histological detail. No significant cytological atypia is seen. 
 
Figure 7: Notochordal Cell Tumours. 
A. Chordoma (H&E x100): The tumour consists of cords of cells with well-defined cytoplasmic 
boundaries, foamy or bubbly cytoplasm and prominent nucleoli. The bubbly quality gives 
rise to the characteristic term “physaliphorous cell”. There are intervening fibrous septae 
and myxoid changes in the background stroma. 
B. Brachyury Expression (IHC x100): Strong nuclear positivity helping to distinguish the tumour 
from a metastatic clear cell carcinoma and chondrosarcoma. 
C. Dedifferentiated chordoma (H&E x40): Chordoma with an adjacent undifferentiated spindle 
cell tumour. Identification of the differentiated component in combination with the 
radiological features and characteristic axial location all support the diagnosis.  
D. Benign Notochordal Cell Tumour (H&E x40): Tumour composed of clear cells with bland 
nuclear features and a notochordal phenotype. There is no cytological atypia, myxoid 
change or necrosis, allowing a confident distinction to be made in most instances.  This 
tumour was seen incidentally following resection of a sacral osteosarcoma.    
 
 
Figure 8 The Ewing Sarcoma Family of Tumours (ESFT) 
A. Ewing sarcoma (H&E x100): Tumour with a monotonous “small round cell” morphology 
composed of cells with scanty cytoplasm. Homer-Wright rosettes may be present, indicative 
of neuroectodermal differentiation.  
B. Immunohistochemistry for CD99 (H&E x100): Strong membranous staining characteristic of 
Ewing sarcoma. This marker has low specificity and must be interpreted in the context of the 
radiological and morphological findings.  
C. Break-apart probe for the EWSR1 gene from the case shown in figure 8A: red and green 
signals split apart indicating a positive result, confirming the diagnosis of Ewing sarcoma. 
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D. CIC-DUX4 rearranged sarcoma (H&E x100): A malignant tumour with a “small round cell” 
morphology. Note that the cells show a more variable degree of pleomorphism and are less 
monotonous that in conventional Ewing sarcoma. 
 
References 
1. Czerniak B. Dorfman and Czerniak's Bone Tumors [electronic resource]. 2nd ed. ed. 
Philadelphia, PA: Elsevier Health Sciences; 2016. 
2. Mirra JM, Gold R, Downs J, Eckardt JJ. A new histologic approach to the differentiation of 
enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. 
Clin Orthop Relat Res. 1985:214-237. 
3. Eefting D, Schrage YM, Geirnaerdt MJ, et al. Assessment of interobserver variability and 
histologic parameters to improve reliability in classification and grading of central 
cartilaginous tumors. Am J Surg Pathol. 2009;33:50-57. 
4. Roitman PD, Farfalli GL, Ayerza MA, Múscolo DL, Milano FE, Aponte-Tinao LA. Is Needle 
Biopsy Clinically Useful in Preoperative Grading of Central Chondrosarcoma of the Pelvis and 
Long Bones? Clin Orthop Relat Res. 2017;475:808-814. 
5. Dahlin DC, Salvador AH. Chondrosarcomas of bones of the hands and feet--a study of 30 
cases. Cancer. 1974;34:755-760. 
6. Nota SP, Braun Y, Schwab JH, van Dijk CN, Bramer JA. The Identification of Prognostic Factors 
and Survival Statistics of Conventional Central Chondrosarcoma. Sarcoma. 
2015;2015:623746. 
7. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in 
central chondrosarcoma and central and periosteal chondromas but not in other 
mesenchymal tumours. J Pathol. 2011;224:334-343. 
8. Damato S, Alorjani M, Bonar F, et al. IDH1 mutations are not found in cartilaginous tumours 
other than central and periosteal chondrosarcomas and enchondromas. Histopathology. 
2012;60:363-365. 
9. Kitsoulis P, Galani V, Stefanaki K, et al. Osteochondromas: review of the clinical, radiological 
and pathological features. In Vivo. 2008;22:633-646. 
10. Bovée JV. Multiple osteochondromas. Orphanet J Rare Dis. 2008;3:3. 
11. Garrison RC, Unni KK, McLeod RA, Pritchard DJ, Dahlin DC. Chondrosarcoma arising in 
osteochondroma. Cancer. 1982;49:1890-1897. 
12. Jäger M, Westhoff B, Portier S, et al. Clinical outcome and genotype in patients with 
hereditary multiple exostoses. J Orthop Res. 2007;25:1541-1551. 
13. Jennes I, de Jong D, Mees K, Hogendoorn PC, Szuhai K, Wuyts W. Breakpoint characterization 
of large deletions in EXT1 or EXT2 in 10 multiple osteochondromas families. BMC Med 
Genet. 2011;12:85. 
14. Frassica FJ, Unni KK, Beabout JW, Sim FH. Dedifferentiated chondrosarcoma. A report of the 
clinicopathological features and treatment of seventy-eight cases. J Bone Joint Surg Am. 
1986;68:1197-1205. 
15. Johnson S, Têtu B, Ayala AG, Chawla SP. Chondrosarcoma with additional mesenchymal 
component (dedifferentiated chondrosarcoma). I. A clinicopathologic study of 26 cases. 
Cancer. 1986;58:278-286. 
16. Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F. Targeting isocitrate dehydrogenase 
(IDH) in cancer. Discov Med. 2016;21:373-380. 
17. Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by 
somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011;43:1262-1265. 
 24 
18. Yang W, Wang J, Moore DC, et al. Ptpn11 deletion in a novel progenitor causes 
metachondromatosis by inducing hedgehog signalling. Nature. 2013;499:491-495. 
19. Bhargava R, Leonard NJ, Chan AK, Spranger J. Autosomal dominant inheritance of 
spondyloenchondrodysplasia. Am J Med Genet A. 2005;135:282-288. 
20. Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define 
chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479-1482. 
21. Amary MF, Berisha F, Mozela R, et al. The H3F3 K36M mutant antibody is a sensitive and 
specific marker for the diagnosis of chondroblastoma. Histopathology. 2016;69:121-127. 
22. de Silva MV, Reid R. Chondroblastoma: varied histologic appearance, potential diagnostic 
pitfalls, and clinicopathologic features associated with local recurrence. Ann Diagn Pathol. 
2003;7:205-213. 
23. Carter JM, Caron BL, Dogan A, Folpe AL. A novel chromogenic in situ hybridization assay for 
FGF23 mRNA in phosphaturic mesenchymal tumors. Am J Surg Pathol. 2015;39:75-83. 
24. Rahimi A, Beabout JW, Ivins JC, Dahlin DC. Chondromyxoid fibroma: a clinicopathologic study 
of 76 cases. Cancer. 1972;30:726-736. 
25. Nord KH, Lilljebjörn H, Vezzi F, et al. GRM1 is upregulated through gene fusion and promoter 
swapping in chondromyxoid fibroma. Nat Genet. 2014;46:474-477. 
26. Nora FE, Dahlin DC, Beabout JW. Bizarre parosteal osteochondromatous proliferations of the 
hands and feet. Am J Surg Pathol. 1983;7:245-250. 
27. Wang L, Motoi T, Khanin R, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in 
mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression 
data. Genes Chromosomes Cancer. 2012;51:127-139. 
28. Atesok KI, Alman BA, Schemitsch EH, Peyser A, Mankin H. Osteoid osteoma and 
osteoblastoma. J Am Acad Orthop Surg. 2011;19:678-689. 
29. Kurt AM, Unni KK, McLeod RA, Pritchard DJ. Low-grade intraosseous osteosarcoma. Cancer. 
1990;65:1418-1428. 
30. Amary F, Berisha F, Ye H, et al. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable 
Marker Defining Benign and Malignant Giant Cell Tumor of Bone. Am J Surg Pathol. 2017. 
31. Zhang J, Nichols KE, Downing JR. Germline Mutations in Predisposition Genes in Pediatric 
Cancer. N Engl J Med. 2016;374:1391. 
32. Behjati S, Tarpey P, Haase K, et al. Recurrent mutation of IGF signalling genes and distinct 
patterns of genomic rearrangement in osteosarcoma. Nat. Commun. 2017;Accepted for 
publication. 
33. Salinas-Souza C, De Andrea C, Bihl M, et al. GNAS mutations are not detected in parosteal 
and low-grade central osteosarcomas. Mod Pathol. 2015;28:1336-1342. 
34. Sheth DS, Yasko AW, Raymond AK, et al. Conventional and dedifferentiated parosteal 
osteosarcoma. Diagnosis, treatment, and outcome. Cancer. 1996;78:2136-2145. 
35. Dujardin F, Binh MB, Bouvier C, et al. MDM2 and CDK4 immunohistochemistry is a valuable 
tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-
osseous lesions of the bone. Mod Pathol. 2011;24:624-637. 
36. Rose PS, Dickey ID, Wenger DE, Unni KK, Sim FH. Periosteal osteosarcoma: long-term 
outcome and risk of late recurrence. Clin Orthop Relat Res. 2006;453:314-317. 
37. Colby RS, Saul RA. Is Jaffe-Campanacci syndrome just a manifestation of neurofibromatosis 
type 1? Am J Med Genet A. 2003;123A:60-63. 
38. Mankin HJ, Trahan CA, Fondren G, Mankin CJ. Non-ossifying fibroma, fibrous cortical defect 
and Jaffe-Campanacci syndrome: a biologic and clinical review. Chir Organi Mov. 2009;93:1-
7. 
39. Roitman PD, Jauk F, Farfalli GL, Albergo JI, Aponte-Tinao LA. Denosumab-Treated Giant Cell 
Tumor of Bone Its Histologic Spectrum and Potential Diagnostic Pitfalls. Hum Pathol. 2017. 
40. Presneau N, Baumhoer D, Behjati S, et al. Diagnostic value of H3F3A mutations in giant cell 
tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1:113-123. 
 25 
41. Amary F, Berisha F, Ye H, et al. H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable 
marker defining benign and malignant giant cell tumour of bone. Am. J. Surg. Pathol. 
2017;Accepted for publication. 
42. Erickson-Johnson MR, Chou MM, Evers BR, et al. Nodular fasciitis: a novel model of transient 
neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 2011;91:1427-1433. 
43. Idowu BD, Thomas G, Frow R, Diss TC, Flanagan AM. Mutations in SH3BP2, the cherubism 
gene, were not detected in central or peripheral giant cell tumours of the jaw. Br J Oral 
Maxillofac Surg. 2008;46:229-230. 
44. Flanagan AM, Speight PM. Giant cell lesions of the craniofacial bones. Head Neck Pathol. 
2014;8:445-453. 
45. Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal 
manifestations of fibrous dysplasia. Orphanet J Rare Dis. 2012;7 Suppl 1:S4. 
46. Reed RJ. Fibrous dysplasia of bone. A review of 25 cases. Arch Pathol. 1963;75:480-495. 
47. Gray MJ, Kannu P, Sharma S, et al. Mutations Preventing Regulated Exon Skipping in MET 
Cause Osteofibrous Dysplasia. Am J Hum Genet. 2015;97:837-847. 
48. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and 
survival patterns in the United States, 1973-1995. Cancer Causes Control. 2001;12:1-11. 
49. Stacchiotti S, Sommer J, Group CGC. Building a global consensus approach to chordoma: a 
position paper from the medical and patient community. Lancet Oncol. 2015;16:e71-83. 
50. Scheipl S, Barnard M, Cottone L, et al. EGFR inhibitors identified as a potential treatment for 
chordoma in a focused compound screen. J Pathol. 2016;239:320-334. 
51. Tirabosco R, Mangham DC, Rosenberg AE, et al. Brachyury expression in extra-axial skeletal 
and soft tissue chordomas: a marker that distinguishes chordoma from mixed 
tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32:572-580. 
52. Bjornsson J, Wold LE, Ebersold MJ, Laws ER. Chordoma of the mobile spine. A 
clinicopathologic analysis of 40 patients. Cancer. 1993;71:735-740. 
53. Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing 
sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28:3284-3291. 
54. Antonescu C. Round cell sarcomas beyond Ewing: emerging entities. Histopathology. 
2014;64:26-37. 
55. Hung YP, Fletcher CD, Hornick JL. Evaluation of NKX2-2 expression in round cell sarcomas 
and other tumors with EWSR1 rearrangement: imperfect specificity for Ewing sarcoma. Mod 
Pathol. 2016;29:370-380. 
56. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a 
clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40:818-831. 
 
